AAPG Relative Valuation
AAPG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AAPG is overvalued; if below, it's undervalued.
Historical Valuation
Ascentage Pharma Group International (AAPG) is now in the Undervalued zone, suggesting that its current forward PS ratio of 17.10 is considered Undervalued compared with the five-year average of -29.05. The fair price of Ascentage Pharma Group International (AAPG) is between 69.66 to 96.75 according to relative valuation methord. Compared to the current price of 32.88 USD , Ascentage Pharma Group International is Undervalued By 52.8%.
Relative Value
Fair Zone
69.66-96.75
Current Price：32.88
52.8%
Undervalued
-45.83
PE
1Y
3Y
5Y
Trailing
Forward
-493.76
EV/EBITDA
Ascentage Pharma Group International. (AAPG) has a current EV/EBITDA of -493.76. The 5-year average EV/EBITDA is -150.32. The thresholds are as follows: Strongly Undervalued below -567.97, Undervalued between -567.97 and -359.15, Fairly Valued between 58.51 and -359.15, Overvalued between 58.51 and 267.33, and Strongly Overvalued above 267.33. The current Forward EV/EBITDA of -493.76 falls within the Undervalued range.
-59.61
EV/EBIT
Ascentage Pharma Group International. (AAPG) has a current EV/EBIT of -59.61. The 5-year average EV/EBIT is -43.08. The thresholds are as follows: Strongly Undervalued below -93.94, Undervalued between -93.94 and -68.51, Fairly Valued between -17.65 and -68.51, Overvalued between -17.65 and 7.78, and Strongly Overvalued above 7.78. The current Forward EV/EBIT of -59.61 falls within the Historic Trend Line -Fairly Valued range.
17.10
PS
Ascentage Pharma Group International. (AAPG) has a current PS of 17.10. The 5-year average PS is 23.89. The thresholds are as follows: Strongly Undervalued below 6.27, Undervalued between 6.27 and 15.08, Fairly Valued between 32.70 and 15.08, Overvalued between 32.70 and 41.50, and Strongly Overvalued above 41.50. The current Forward PS of 17.10 falls within the Historic Trend Line -Fairly Valued range.
-91.89
P/OCF
Ascentage Pharma Group International. (AAPG) has a current P/OCF of -91.89. The 5-year average P/OCF is -54.73. The thresholds are as follows: Strongly Undervalued below -137.87, Undervalued between -137.87 and -96.30, Fairly Valued between -13.15 and -96.30, Overvalued between -13.15 and 28.42, and Strongly Overvalued above 28.42. The current Forward P/OCF of -91.89 falls within the Historic Trend Line -Fairly Valued range.
-54.90
P/FCF
Ascentage Pharma Group International. (AAPG) has a current P/FCF of -54.90. The 5-year average P/FCF is -35.83. The thresholds are as follows: Strongly Undervalued below -77.04, Undervalued between -77.04 and -56.43, Fairly Valued between -15.22 and -56.43, Overvalued between -15.22 and 5.39, and Strongly Overvalued above 5.39. The current Forward P/FCF of -54.90 falls within the Historic Trend Line -Fairly Valued range.
Ascentage Pharma Group International (AAPG) has a current Price-to-Book (P/B) ratio of 120.00. Compared to its 3-year average P/B ratio of 141.79 , the current P/B ratio is approximately -15.37% higher. Relative to its 5-year average P/B ratio of 141.79, the current P/B ratio is about -15.37% higher. Ascentage Pharma Group International (AAPG) has a Forward Free Cash Flow (FCF) yield of approximately -1.02%. Compared to its 3-year average FCF yield of -1.64%, the current FCF yield is approximately -37.70% lower. Relative to its 5-year average FCF yield of -1.64% , the current FCF yield is about -37.70% lower.
120.00
P/B
Median3y
141.79
Median5y
141.79
-1.02
FCF Yield
Median3y
-1.64
Median5y
-1.64
Competitors Valuation Multiple
The average P/S ratio for AAPG's competitors is 105.12, providing a benchmark for relative valuation. Ascentage Pharma Group International Corp (AAPG) exhibits a P/S ratio of 17.10, which is -83.73% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of AAPG increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of AAPG in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Ascentage Pharma Group International (AAPG) currently overvalued or undervalued?
What is Ascentage Pharma Group International (AAPG) fair value?
How does AAPG's valuation metrics compare to the industry average?
What is the current P/B ratio for Ascentage Pharma Group International (AAPG) as of Dec 08 2025?
What is the current FCF Yield for Ascentage Pharma Group International (AAPG) as of Dec 08 2025?
What is the current Forward P/E ratio for Ascentage Pharma Group International (AAPG) as of Dec 08 2025?